DiogenX Company
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Industry:
Geroscience
Headquarters:
Marseille, Provence-Alpes-Cote d'Azur, France
Zip:
1-10
Founded Date:
2019-01-01
Employees Number:
1-10
Acquisitions Number:
3
Investors Number:
5069926
Total Funding:
Less than $1M
Estimated Revenue:
Less than $1M
Last Funding Date:
Seed
Last Funding Type:
Seed
Register and Claim Ownership